Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer K R
Department of Orthopedics, University of Colorado Health Sciences Center, Denver.
Eur J Surg Oncol. 2003 May;29(4):379-82. doi: 10.1053/ejso.2002.1415.
Osteosarcoma is the most frequent malignant bone tumor with a peak incidence in the second and third decade of life. Evaluation of prognosis of patients with osteosarcoma is limited to clinical parameters whereas molecular markers of tumor aggression have not yet been identified. Inhibition of apoptotic cell death could play a role in the development or progression of neoplasia. Survivin is a member of the inhibitor of apoptosis (IAP) protein gene family and is expressed both during normal fetal development and in human cancer.
The localization and distribution of survivin was investigated immunohistochemically in high-grade osteosarcomas by an indirect immunoperoxidase method.
Survivin was detected in the cytoplasm in 23/40 and in the nucleus in 20/40 cases of osteosarcoma. Nuclear localization of survivin expression was significantly correlated with a prolonged survival (P=0.0347) but cytoplasmic staining showed no correlation with patient outcome.
The results of this study indicates that the evaluation of survivin expression might be a useful prognostic marker in osteosarcoma. Patients with osteosarcoma exhibiting nuclear survivin expression could potentially benefit from stratification of neoadjuvant chemotherapy.
骨肉瘤是最常见的恶性骨肿瘤,发病高峰在生命的第二个和第三个十年。骨肉瘤患者预后的评估仅限于临床参数,而肿瘤侵袭的分子标志物尚未确定。凋亡细胞死亡的抑制可能在肿瘤形成或进展中起作用。生存素是凋亡抑制蛋白(IAP)基因家族的成员,在正常胎儿发育和人类癌症中均有表达。
采用间接免疫过氧化物酶法,通过免疫组织化学研究高级别骨肉瘤中生存素的定位和分布。
在40例骨肉瘤病例中,23例在细胞质中检测到生存素,20例在细胞核中检测到生存素。生存素表达的核定位与生存期延长显著相关(P = 0.0347),但细胞质染色与患者预后无关。
本研究结果表明,生存素表达的评估可能是骨肉瘤中一种有用的预后标志物。骨肉瘤患者生存素表达呈核型可能从新辅助化疗分层中获益。